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Radiation damage to normal tissues is one of the most serious concerns in radiation
therapy, and the tolerance dose of the normal tissues limits the therapeutic dose
to the patients. p53 is well known as a transcription factor closely associated with
radiation-induced cell death. We recently demonstrated the protective effects of several
p53 regulatory agents against low-LET X- or γ-ray-induced damage. Although it was
reported that high-LET heavy ion radiation (>85 keV/µm) could cause p53-independent
cell death in some cancer cell lines, whether there is any radioprotective effect of the p53
regulatory agents against the high-LET radiation injury in vivo is still unclear. In the present
study, we verified the efficacy of these agents on bone marrow and intestinal damages
induced by high-LET heavy-ion irradiation in mice. We used a carbon-beam (14 keV/µm)
that was shown to induce a p53-dependent effect and an iron-beam (189 keV/µm) that
was shown to induce a p53-independent effect in a previous study. Vanadate significantly
improved 60-day survival rate in mice treated with total-body carbon-ion (p < 0.0001)
or iron-ion (p < 0.05) irradiation, indicating its effective protection of the hematopoietic
system from radiation injury after high-LET irradiation over 85 keV/µm. 5CHQ also
significantly increased the survival rate after abdominal carbon-ion (p < 0.02), but not
iron-ion irradiation, suggesting the moderate relief of the intestinal damage. These results
demonstrated the effectiveness of p53 regulators on acute radiation syndrome induced
by high-LET radiation.
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INTRODUCTION
In recent years, several molecular target drugs have been developed for reducing acute radiation
toxicities (1–8). Although the effects of these radioprotectors have been demonstrated by
experiments with low-LET radiation, we speculated that such cell death-regulating agents were
also effective for protection against particle beam injury, because their radioprotective efficacies do
not depend on a radical scavenging action, which is mainly effective for radiation injury caused by
indirect action (9).
Although particle therapy has characteristic advantages by the superior dose distribution,
the risks of radiation injury in normal tissues still determine the limits of a tolerable
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dose, thus cell death-regulating agents are expected as one of the
non-invasive measures to reduce adverse events from occurring
in organs at risk (OAR). This is especially necessary to protect
OAR close to the tumor and to further improve hypofractionated
regimens to increase the dose per fraction while suppressing the
side effects of acute injury (10–13). In addition, although the
estimated exposure dose is not quite high, it will be useful as
a basic study for the development of protective agents against
cosmic rays. The potential health risk in a manned interplanetary
mission with a long duration up to 3 years should be reduced
by proper countermeasures and the absorbed doses estimated
for the largest solar particle events would be higher than 1Gy
and could reach 10Gy in a thinly shielded spacecraft (14). Our
knowledge from radiobiology indicates clearly that a dose at this
latitude of even low-LET photon radiation could definitely cause
significant detrimental biological effects. There are two major
radiation sources of space radiation: galactic cosmic rays (GCRs)
and solar particle events. GCRs consist of 85% low LET protons,
14% helium ions and 1% high atomic number and energy (HZE)
particles including iron particles (15). Although these HZE
particles make up only 1% of GCRs, they are high-LET particle
radiations. They contribute to 21% of the estimated ionizing dose
equivalent from GCR exposure during interplanetary missions in
deep space and contribute significantly to the overall biological
impact of cosmic rays (16).
p53 regulatory agents are expected to be applied as a
normal tissue-selective radioprotective agent, because these
agents selectively suppress apoptosis of OAR having normal
p53 function and do not protect cancer cells that lost p53
functions (17). Furthermore, when the suppression of p53 is
transient, unlike constitutive p53-knockout, p53 suppression
does not promote carcinogenesis (18). On the other hand, it
has been demonstrated by using tumor-derived cultured cells
that particle beam-induced cell death does not show a p53
dependency on the LET of 85 keV/µm or more (19). It is unclear
whether particle beam injuries in the bone marrow and intestinal
epithelium, which are highly radiosensitive among OAR, are
p53-dependent events.
We have already found sodium orthovanadate (vanadate)
as an effective “p53 inhibitor” for bone marrow death and 5-
chloro-8-quinolinol (5CHQ) as an effective “p53 modulator”
for intestinal death (4, 7). Our previous work with low-LET
radiations had demonstrated that vanadate is the strongest p53
inhibitor with many other biological functions; it is significantly
effective against bone marrow death and partially works against
intestinal death in total-body irradiation (TBI) tests, and 5CHQ is
basically a p53 modulator playing important roles in modulating
p53 functions, in particular, activation; it could markedly protect
the intestinal death in abdominal irradiation (ABI) tests but has
a weak radioprotective activity against bone marrow death in
TBI tests. The difference of the spectra against acute radiation
syndrome (ARS) is attributed to that p53 plays distinct roles
in ARS between bone marrow death and intestinal death,
in brief, p53 functions as a promoting factor that induces
apoptosis in bone marrow death and as a resistance factor that
prevents mitotic death in intestinal death (20). In particular, to
demonstrate the protective role of p53, it is necessary to evaluate
the effects of these compounds on the radiation-injured intestine
using the ABI technique to avoid bone marrow death. In general,
this ABI system requires more than twice the dose used in the
TBI test to achieve a lethal effect. In this study, to evaluate the
efficacy of these compounds, mice were irradiated systemically
or abdominally with particle beams and evaluated using 60-day
survival test. Regarding the radiation quality, we used a carbon-
beam (14 keV/µm) that was shown to induce a p53-dependent
effect and an iron-beam (189 keV/µm) that was shown to induce
a p53-independent effect in a previous study (19).
MATERIALS AND METHODS
All animal experiments were performed at National Institute
of Radiological Sciences (NIRS), National Institutes for
Quantum and Radiological Science and Technology (QST). All
experimental protocols (Experimental Animal Research Plans
No. 09-1042 and No. 17-2006) involving mice were reviewed and
approved by The Institutional Animal Care and Use Committee
of the NIRS, QST. The experiments were performed in strict
accordance with the NIRS, QST Guidelines for the Care and Use
of Laboratory Animals.
Animals
Seven weeks-old ICR strain female mice were purchased from
SLC Inc. (Shizuoka, Japan) and maintained in a conventional
animal facility under a 12 h light−12 h dark photoperiod and
controlled temperature (22–24◦C) and humidity (50 ± 5%).
The animals were housed in autoclaved aluminum cages with
sterilized wood chips and allowed to access standard laboratory
chow (MB-1, Funabashi FarmCo., Japan) and acidifiedwater (pH
= 3.0 ± 0.2) ad libitum. The animals were acclimatized to the
laboratory conditions for 1 week before use. To avoid possible
effects from the developmental condition of the animals, 6 weeks-
old mice with a significantly different body weight (more or less
than the mean± 2 SD) were omitted from this study.
Irradiation
For high LET heavy ion irradiation, the monoenergetic ion beam
of carbon and iron particles was generated and accelerated by
a synchrotron, the Heavy Ion Medical Accelerator in Chiba
(HIMAC) at NIRS, QST, Japan (21, 22). The beam energy was
290 MeV/nucleon and 500 MeV/nucleon for carbon- and iron-
beams, and the ion beams were expanded by wobbler magnets
to a 10 cm irradiation field with homogeneous irradiation dose.
Samples were irradiated at the entrance (plateau) region of
the ion beams corresponding to a dose averaged LET value
of about 14 and 189 keV/µm, respectively. The dose rate for
TBI and ABI was at about 2.7 (C-ion)/3.6 (Fe-ion) and 6.1(C-
ion)/5.1(Fe-ion) Gy/min, respectively. For TBI, the mice were
held in a special Lucite columnar container, which was with an
outer diameter of 10 cm and 3 individual cells of the same size
(each mouse in each cell). The mice were in an air-breathing
condition (there were six holes 5mm in diameter in the wall
of each cell). The containers were set on the beam track and
the focused 10 cm diameter carbon- or iron-beam was delivered
to the animals at room temperature without anesthesia. For
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FIGURE 1 | Effect of vanadate on total-body or abdominally irradiated mice with carbon-beam. ICR female mice were i.p. injected with vanadate 30min before
irradiation. Numbers in parenthesis denote the number of mice. (A) Sixty-day survival tests after 7.0 or 7.5 Gy-TBI of ICR mouse subgroups of vehicle alone or 20
mg/kg vanadate. By chi-square test, p < 0.0001, respectively. (B) Sixty-day survival tests after 12, 15, or 18 Gy-ABI of ICR mouse subgroups of vehicle alone or 20
mg/kg vanadate. By chi-square test, p = not significant (N/S), respectively.
ABI, the animals were anesthetized by a combination anesthetic
(0.3 mg/kg of medetomidine, 4.0 mg/kg of midazolam, and 5.0
mg/kg of butorphanol), fixed on a special Lucite plate using
medical adhesive tapes, and then set on the beam track. The
10 cm diameter carbon- or iron-beam was further collimated to
a 2 cm slit by 5 cm brass collimators and delivered locally to the
whole abdominal area of the mouse. Irradiation was performed
at room temperature.
Sodium Orthovanadate (Vanadate) and
5-chloro-8-quinolinol (5CHQ)
Vanadate was purchased from Sigma-Aldrich (Sigma-Aldrich,
St. Louis, MO, USA). The physiological normal saline (NS)
(Otsuka Pharmaceutical Co., Ltd., Japan) was used as a solvent
to make vanadate solution (2 mg/mL in NS solution). Vanadate
at dose of 20 mg/kg body weight or vehicle (NS solution) was
administered to the mouse 30min before irradiation by a single
intraperitoneal injection. 5CHQ was purchased fromWako Pure
Chemical Industry (Wako Pure Chemical Industry, Co., Ltd.,
Japan) and recrystallized from ethanol for reducing possible
cytotoxicity. Injection solution was prepared using dimethyl
sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA) and
olive oil (Wako Pure Chemical Industry, Co., Ltd., Japan) as
solvents. Animals were given a single intraperitoneal injection of
5CHQ at a dose of 60 mg/kg body weight or vehicle (20% DMSO
in olive oil) 30–60min before irradiation.
Survival Test
Survival of the animals was monitored daily up to 60 days after
irradiation. For statistical analysis, log-rank test was performed
when the number of animals per group was 20 or more, and chi-
square test was performed when the number animals was <20
using Microsoft Excel with the add-in software Statcel 4 (OMS
publisher Ltd, Saitama, Japan).
RESULTS
Vanadate Is Highly Effective in Protection
of Carbon-Beam TBI-Induced Death, but
Not Protective Against ABI-Induced Death
At first, the protective effect of vanadate was examined in carbon-
beam irradiation experiments (290 MeV/nucleon, mono-beam,
LET 14 keV/µm). In the TBI experiments, 7.0, and 7.5Gy were
delivered to 8-week-old female ICR mice (12 mice in each
irradiation group), and the survival rate was observed for 60
days (Figure 1A). In 7.0 and 7.5 Gy-TBI mice, the survival rate
at 60 days was 8.3 and 0% in the vehicle-administered group,
whereas the survival rate in the vanadate-administered group was
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FIGURE 2 | Effect of vanadate on iron-beam total-body irradiated mice. ICR
female mice were i.p. injected with vanadate 30min before irradiation.
Numbers in parenthesis denote the number of mice. Sixty-day survival tests
after 7.6 or 8.0 Gy-TBI of ICR mouse subgroups of vehicle alone or 20 mg/kg
vanadate. By log-rank test, p < 0.05, respectively.
92 and 83%, respectively, showing a significant radioprotective
effect of vanadate (p < 0.0001). In order to show the killing
effect for carbon-beam ABI, we delivered 12, 15, and 18Gy to
mice, and the survival rate was observed for 60 days (Figure 1B).
At the administered doses, a dose at 12 Gy-ABI was not lethal
and no protective effect of vanadate was observed in 15Gy or
18 Gy-ABI mice. These data clearly demonstrate that vanadate
has a protective effect against the bone marrow death induced by
carbon-beam TBI, while that it is ineffective against the intestinal
death induced by carbon-beam ABI.
Vanadate Is Also Effective in Protection of
Iron-Beam TBI-Induced Death
Second, the protective effect of vanadate was examined in iron-
beamTBI experiments (500MeV/nucleon, mono-beam, LET 189
keV/µm). In the TBI experiments, 7.6 and 8.0Gy were delivered
to 8-week-old female ICR mice (24 mice in each irradiation
group), and the survival rate was observed for 60 days (Figure 2).
In 7.6 and 8.0 Gy-TBI mice, the survival rate at 60 days was
29 and 17% in the vehicle-administered group, whereas the
survival rate in the vanadate-administered groupwas 63 and 46%,
respectively, showing a statistically significant protective effect of
vanadate (p< 0.05), although the surviving rates were lower than
those of carbon-beam experiments. These findings suggest that
p53 inhibition could also suppress bone marrow death induced
by high LET radiation with LET value exceeding 85 keV/µm.
5CHQ Is Effective in Carbon-Beam
ABI-Induced Death, but Not Protective
Against Carbon-Beam TBI-Induced Death
and Iron-Beam ABI-Induced Death
We also investigated the protective effect of 5CHQ, a p53
modulator which has an agonistic activity of activating
radioprotective functions of p53, on the particle beam-irradiated
mice. As previously reported, 5CHQ is more protective against
ABI-induced intestinal death than in TBI-induced bone marrow
death in mice, albeit in low-LET radiation experiments (7).
Firstly, we examined the carbon-beam TBI experiments and
8.0 and 8.5Gy were delivered to 8-week-old female ICR mice
(12 mice in each irradiation group) (Figure 3A). In the TBI
experiments with vehicle DMSO, a slightly higher dose than
those with vehicle saline was required to achieve a lethal effect
and no protective effect of 5CHQ was observed in any group of
systemically irradiated mice. Next, the particle beam protective
effect of 5CHQ was evaluated using abdominally irradiated mice.
In the carbon-beam ABI experiment, a dose at 16.5Gy was
delivered to 8-week-old female ICR mice (36 mice in each
irradiation group) (Figure 3B). As a result, the survival rate at
60 days was 44% in the vehicle-administered group, whereas the
survival rate in the 5CHQ-administered group was 70%, showing
a statistically significant protective effect of 5CHQ (p < 0.02).
We also examined the protective effect of 5CHQ in the iron-
beam ABI experiments (Figure 3C). At the administered doses,
a dose at 11 Gy-ABI was not lethal and no protective effect of
vanadate was observed in 12Gy or 12.5 Gy-ABI mice. These
data demonstrate that 5CHQ has a protective effect against the
intestinal death induced by carbon-beam ABI, while that it is
ineffective against that induced by iron-beam ABI.
DISCUSSION
In this study, we evaluated the protective activity of p53
regulatory agents against bone marrow death by particle beam
TBI and intestinal death by particle beam ABI in the mouse
models. At first, considering that iron-beam causes more severe
damage to cells than carbon-beam at the same dose and saving
animal lives whenever potentially applicable, tests for “vanadate
vs. Fe-beam ABI” and “5CHQ vs. Fe-beam TBI” had not been
performed as these agents showed ineffective against carbon-
beam in the corresponding tests (Figures 1B, 3A).
Considering that vanadate inhibits p53, the results that
vanadate was highly effective in the TBI experiments, and
no protective effect was observed in the ABI experiments are
appropriate. The ineffectiveness of vanadate against intestinal
death by ABI was also confirmed by low-LET X-ray ABI
experiments (Nishiyama et al., manuscript in preparation).
Because these results are consistent with reports of p53’s tissue
response that promotes cell death in the bone marrow and is
protective in the intestine upon radiation injury (20). Of note,
when comparing themouse survival after carbon- and iron-beam
injuries, iron-beam injury is characterized by the late occurrence
of deaths even 30–60 days after irradiation (Figures 1, 2). This
delayed iron-beam damage was suppressed by vanadate. The
cause of delayed death is not clear, it may not be due to the bone
marrow suppression when taking into account the short life span
of the hematopoietic lineage cells. As such a late fatal radiation
injury, radiation angiopathy caused by a delayed cell death of
endothelial cells is well known (23). Further studies are needed
to explore the cause of death using different approaches such
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FIGURE 3 | Effect of 5CHQ on total-body or abdominally irradiated mice with carbon- or iron-beam. ICR female mice were i.p. injected with 5CHQ 30–60min before
irradiation. Numbers in parenthesis denote the number of mice. (A) Sixty-day survival tests after 8.0 or 8.5 Gy-TBI of ICR mouse subgroups of vehicle alone or 60
mg/kg 5CHQ. By chi-square test, p = N/S, respectively. (B) Sixty-day survival tests after 16.5Gy carbon-beam ABI of ICR mouse subgroups of vehicle alone or 60
mg/kg 5CHQ. By log-rank test, p < 0.02. (C) Sixty-day survival tests after 11, 12, or 12.5Gy iron-beam ABI of ICR mouse subgroups of vehicle alone or 60 mg/kg
5CHQ. By chi-square test, p = N/S, respectively.
as pathological examinations or bone marrow transplantation.
In any case, it is clear that there are cell populations that can
avoid the fate of cell death even after exposure to particle beams
with an LET value higher than 85 keV/µm by pharmaceutically
regulating cell death machinery. The dense lesions induced by
these high-LET radiations are considered to be too severe to
be regulated by p53 (19). Our data demonstrate that even in
such a circumstance, at least some cells are rescued by p53
regulatory agent. It is also considered that vanadate has various
activities such as protein tyrosine phosphatase inhibition (24, 25)
and activates radioresistant factors other than p53 to exert its
radioprotective activity. We will focus our next research on
solving these research issues.
As shown in Figure 3, 5CHQ was effective against carbon-
beam intestinal injury, but ineffective against carbon-beam
bone marrow injury and iron-beam intestinal injury. The
ineffectiveness of 5CHQ for iron-beam intestinal injury may
suggest its activity was not strong enough as a p53 modulator
rather than the limit of therapeutic strategies for suppressing
intestinal death by p53 modulators. The discovery of a p53
modulator with a stronger activity than 5CHQmight improve the
protective effect. Considering that the current clinical heavy ion
radiotherapy is performed using carbon beams for the treatment
of tumors in the pelvic region, suppression of radiation intestinal
disorders by application of p53 modulators is expected to be a
useful therapeutic strategy.
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